{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:00:34Z","timestamp":1792800034671,"version":"4.5.0"},"reference-count":332,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"funder":[{"DOI":"10.13039\/100011010","name":"European SocieTy for Radiotherapy and Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022438","name":"European Association for Cardio-Thoracic Surgery","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022438","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008593","name":"European Respiratory Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Society of Thoracic Surgeons","id":[{"id":"https:\/\/ror.org\/044b6j563","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2019,10,17]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:p>\n                    The European Respiratory Society (ERS)\/European Society of Thoracic Surgeons (ESTS)\/European Association for Cardio-Thoracic Surgery (EACTS)\/European Society for Radiotherapy and Oncology (ESTRO) task force brought together experts to update previous 2009 ERS\/ESTS guidelines on management of malignant pleural mesothelioma (MPM), a rare cancer with globally poor outcome, after a systematic review of the 2009\u20132018 literature. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach. The evidence syntheses were discussed and recommendations formulated by this multidisciplinary group of experts. Diagnosis: pleural biopsies remain the gold standard to confirm the diagnosis, usually obtained by thoracoscopy but occasionally\n                    <jats:italic>via<\/jats:italic>\n                    image-guided percutaneous needle biopsy in cases of pleural symphysis or poor performance status. Pathology: standard staining procedures are insufficient in \u223c10% of cases, justifying the use of specific markers, including\n                    <jats:italic>BAP-1<\/jats:italic>\n                    and\n                    <jats:italic>CDKN2A<\/jats:italic>\n                    (\n                    <jats:italic>p16<\/jats:italic>\n                    ) for the separation of atypical mesothelial proliferation from MPM. Staging: in the absence of a uniform, robust and validated staging system, we advise using the most recent 2016 8th TNM (tumour, node, metastasis) classification, with an algorithm for pre-therapeutic assessment. Monitoring: patient's performance status, histological subtype and tumour volume are the main prognostic factors of clinical importance in routine MPM management. Other potential parameters should be recorded at baseline and reported in clinical trials. Treatment: (chemo)therapy has limited efficacy in MPM patients and only selected patients are candidates for radical surgery. New promising targeted therapies, immunotherapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach, including radical surgery, should be treated as part of clinical trials in MPM-dedicated centres.\n                  <\/jats:p>","DOI":"10.1183\/13993003.00953-2019","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T20:24:46Z","timestamp":1590438286000},"page":"1900953","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":243,"title":["ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma"],"prefix":"10.1183","volume":"55","author":[{"given":"Arnaud","family":"Scherpereel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Berghmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Psallidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Glatzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rigau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3988-1792","authenticated-orcid":false,"given":"Philippe","family":"Astoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Servet","family":"B\u00f6l\u00fckbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Coolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"De Bondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8975-6562","authenticated-orcid":false,"given":"Valerie","family":"Durieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Galateau-Salle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5807-9503","authenticated-orcid":false,"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Ali","family":"Hoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Klepetko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Lacourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"McElnay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick A.","family":"Maskell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Mutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4323-6406","authenticated-orcid":false,"given":"Jean-Claude","family":"Pairon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Van Schil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"van Meerbeeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Weder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cardillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Martin","family":"Putora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"2026061109500502000_55.6.1900953.1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3520"},{"key":"2026061109500502000_55.6.1900953.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.42"},{"key":"2026061109500502000_55.6.1900953.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30100-1"},{"key":"2026061109500502000_55.6.1900953.4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-211321"},{"key":"2026061109500502000_55.6.1900953.5","doi-asserted-by":"publisher","DOI":"10.1200\/JC0.2017.76.6394"},{"key":"2026061109500502000_55.6.1900953.6","unstructured":"National Comprehensive Cancer Network (NCCN) . Malignant Pleural Mesothelioma Guidelines Version 2.2018 . NCCN , 2018. www.nccn.org\/professionals\/physician_gls\/pdf\/mpm_blocks.pdf"},{"key":"2026061109500502000_55.6.1900953.7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv199"},{"key":"2026061109500502000_55.6.1900953.8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00063109"},{"key":"2026061109500502000_55.6.1900953.9","unstructured":"Sackett DL . Evidence-Based Medicine: How to Practice and Teach EBM. New York, Edinburgh, Churchill Livingstone, 2000."},{"key":"2026061109500502000_55.6.1900953.10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/0019-5278.146897","article-title":"Global mesothelioma epidemic: trend and features","volume":"18","author":"Bianchi","year":"2014","journal-title":"Indian J Occup Environ Med"},{"key":"2026061109500502000_55.6.1900953.11","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.11.086678"},{"key":"2026061109500502000_55.6.1900953.12","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2017-104298"},{"key":"2026061109500502000_55.6.1900953.13","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00007014"},{"key":"2026061109500502000_55.6.1900953.14","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.13.132118"},{"key":"2026061109500502000_55.6.1900953.15","first-page":"68","article-title":"Incidence of malignant mesothelioma in New Zealand and Australia: a global snapshot","volume":"128","author":"Soberg","year":"2015","journal-title":"N Z Med J"},{"key":"2026061109500502000_55.6.1900953.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2011.01975.x"},{"key":"2026061109500502000_55.6.1900953.17","doi-asserted-by":"publisher","DOI":"10.1002\/ajim.21015"},{"key":"2026061109500502000_55.6.1900953.18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26229"},{"key":"2026061109500502000_55.6.1900953.19","doi-asserted-by":"crossref","first-page":"2641646","DOI":"10.17061\/phrp2641646","article-title":"Mesothelioma trends in the ACT and comparisons with the rest of Australia","volume":"26","author":"Korda","year":"2016","journal-title":"Public Health Res Pract"},{"key":"2026061109500502000_55.6.1900953.20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/1753-6405.12503","article-title":"Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972\u20132009","volume":"40","author":"Soeberg","year":"2016","journal-title":"Aust N Z J Public Health"},{"key":"2026061109500502000_55.6.1900953.21","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2015-103309"},{"key":"2026061109500502000_55.6.1900953.22","doi-asserted-by":"publisher","DOI":"10.1002\/ajim.22442"},{"key":"2026061109500502000_55.6.1900953.23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1179\/2049396714Y.0000000058","article-title":"Asbestos in Belgium: an underestimated health risk. The evolution of mesothelioma mortality rates (1969-2009)","volume":"20","author":"Van den Borre","year":"2014","journal-title":"Int J Occup Environ Health"},{"key":"2026061109500502000_55.6.1900953.24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12995-016-0127-4","article-title":"Malignant mesothelioma incidence by nation-wide cancer registry: a population-based study","volume":"11","author":"Tomasson","year":"2016","journal-title":"J Occup Med Toxicol"},{"key":"2026061109500502000_55.6.1900953.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-014-0368-4"},{"key":"2026061109500502000_55.6.1900953.26","first-page":"97","article-title":"Incidence of malignant mesothelioma in Germany 2009-2013","volume":"28","author":"Lehnert","year":"2017","journal-title":"Cancer Causes Control"},{"key":"2026061109500502000_55.6.1900953.27","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1097\/CEJ.0000000000000384","article-title":"Time trends and spatial patterns in the mesothelioma incidence in Slovenia, 1961-2014","volume":"26","author":"Zadnik","year":"2017","journal-title":"Eur J Cancer Prev"},{"key":"2026061109500502000_55.6.1900953.28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/risa.12887","article-title":"Ambient asbestos fiber concentrations and long-term trends in pleural mesothelioma incidence between urban and rural areas in the United States (1973-2012)","volume":"38","author":"Glynn","year":"2018","journal-title":"Risk Anal"},{"key":"2026061109500502000_55.6.1900953.29","doi-asserted-by":"publisher","DOI":"10.1179\/2049396712Y.0000000016"},{"key":"2026061109500502000_55.6.1900953.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.20324"},{"key":"2026061109500502000_55.6.1900953.31","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318275b346"},{"key":"2026061109500502000_55.6.1900953.32","doi-asserted-by":"publisher","DOI":"10.1136\/oem.2010.062182"},{"key":"2026061109500502000_55.6.1900953.33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canep.2013.12.002","article-title":"Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009","volume":"38","author":"Jennings","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"2026061109500502000_55.6.1900953.34","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24711"},{"key":"2026061109500502000_55.6.1900953.35","first-page":"A4592","article-title":"Regional differences in incidence of malignant mesothelioma in Denmark","volume":"60","author":"Skammeritz","year":"2013","journal-title":"Dan Med J"},{"key":"2026061109500502000_55.6.1900953.36","doi-asserted-by":"publisher","DOI":"10.1177\/1403494815596500"},{"key":"2026061109500502000_55.6.1900953.37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.21147\/j.issn.1000-9604.2017.04.09","article-title":"Epidemiology and trend analysis on malignant mesothelioma in China","volume":"29","author":"Zhao","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"2026061109500502000_55.6.1900953.38","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.canep.2015.08.007","article-title":"The next mesothelioma wave: mortality trends and forecast to 2030 in Brazil","volume":"39","author":"Algranti","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"2026061109500502000_55.6.1900953.39","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajim.22065","article-title":"A decade of malignant mesothelioma surveillance in Korea","volume":"55","author":"Jung","year":"2012","journal-title":"Am J Ind Med"},{"key":"2026061109500502000_55.6.1900953.40","doi-asserted-by":"crossref","first-page":"e0183404","DOI":"10.1371\/journal.pone.0183404","article-title":"Estimated future incidence of malignant mesothelioma in South Korea: projection from 2014 to 2033","volume":"12","author":"Kwak","year":"2017","journal-title":"PLoS One"},{"key":"2026061109500502000_55.6.1900953.41","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-1107-z"},{"key":"2026061109500502000_55.6.1900953.42","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1289\/ehp.0900868","article-title":"Are current or future mesothelioma epidemics in Hong Kong the tragic legacy of uncontrolled use of asbestos in the past?","volume":"118","author":"Tse","year":"2010","journal-title":"Environ Health Perspect"},{"key":"2026061109500502000_55.6.1900953.43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-528"},{"key":"2026061109500502000_55.6.1900953.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60412-7"},{"key":"2026061109500502000_55.6.1900953.45","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690105"},{"key":"2026061109500502000_55.6.1900953.46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5301\/tj.5000559","article-title":"Data quality in rare cancers registration: the report of the RARECARE data quality study","volume":"103","author":"Trama","year":"2017","journal-title":"Tumori"},{"key":"2026061109500502000_55.6.1900953.47","doi-asserted-by":"publisher","DOI":"10.1080\/10408440802273156"},{"key":"2026061109500502000_55.6.1900953.48","first-page":"718","article-title":"Latent period for malignant mesothelioma of occupational origin","volume":"34","author":"Lanphear","year":"1992","journal-title":"J Occup Med"},{"key":"2026061109500502000_55.6.1900953.49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ajim.20780","article-title":"Case-control study of pleural mesothelioma in workers with social security in Mexico","volume":"53","author":"Aguilar-Madrid","year":"2010","journal-title":"Am J Ind Med"},{"key":"2026061109500502000_55.6.1900953.50","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605637"},{"key":"2026061109500502000_55.6.1900953.51","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203744"},{"key":"2026061109500502000_55.6.1900953.52","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2015-102803"},{"key":"2026061109500502000_55.6.1900953.53","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jtho.2017.04.002","article-title":"Epidemiology of environmental exposure and malignant mesothelioma","volume":"12","author":"Liu","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.54","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2016-104002"},{"key":"2026061109500502000_55.6.1900953.55","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1289\/ehp.1002862","article-title":"Pleural mesothelioma in New Caledonia: associations with environmental risk factors","volume":"119","author":"Baumann","year":"2011","journal-title":"Environ Health Perspect"},{"key":"2026061109500502000_55.6.1900953.56","doi-asserted-by":"publisher","DOI":"10.1007\/s10653-013-9518-y"},{"key":"2026061109500502000_55.6.1900953.57","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ijheh.2013.07.008","article-title":"Lung cancer and mesothelioma risk assessment for a population environmentally exposed to asbestos","volume":"217","author":"Bourgault","year":"2014","journal-title":"Int J Hyg Environ Health"},{"key":"2026061109500502000_55.6.1900953.58","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12885-015-1301-2","article-title":"Epidemiological patterns of asbestos exposure and spatial clusters of incident cases of malignant mesothelioma from the Italian national registry","volume":"15","author":"Corfiati","year":"2015","journal-title":"BMC Cancer"},{"key":"2026061109500502000_55.6.1900953.59","first-page":"419","article-title":"Pleural mesothelioma in household members of asbestos-exposed workers in Friuli Venezia Giulia, Italy","volume":"30","author":"D'Agostin","year":"2017","journal-title":"Int J Occup Med Environ Health"},{"key":"2026061109500502000_55.6.1900953.60","doi-asserted-by":"publisher","DOI":"10.1038\/jes.2009.56"},{"key":"2026061109500502000_55.6.1900953.61","first-page":"322","article-title":"Mesothelioma incidence in the neighbourhood of an asbestos-cement plant located in a national priority contaminated site","volume":"50","author":"Fazzo","year":"2014","journal-title":"Ann Ist Super Sanita"},{"key":"2026061109500502000_55.6.1900953.62","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00017011"},{"key":"2026061109500502000_55.6.1900953.63","doi-asserted-by":"publisher","DOI":"10.1136\/oem.2009.050336"},{"key":"2026061109500502000_55.6.1900953.64","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph10115629"},{"key":"2026061109500502000_55.6.1900953.65","first-page":"A4902","article-title":"Almost half of women with malignant mesothelioma were exposed to asbestos at home through their husbands or sons","volume":"61","author":"Langhoff","year":"2014","journal-title":"Dan Med J"},{"key":"2026061109500502000_55.6.1900953.66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.scitotenv.2012.02.047","article-title":"Industrial pollution and pleural cancer mortality in Spain","volume":"424","author":"L\u00f3pez-Abente","year":"2012","journal-title":"Sci Total Environ"},{"key":"2026061109500502000_55.6.1900953.67","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2014-102297"},{"key":"2026061109500502000_55.6.1900953.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2014.10.016"},{"key":"2026061109500502000_55.6.1900953.69","doi-asserted-by":"publisher","DOI":"10.1136\/oem.2009.047019"},{"key":"2026061109500502000_55.6.1900953.70","doi-asserted-by":"publisher","DOI":"10.5694\/mja11.10125"},{"key":"2026061109500502000_55.6.1900953.71","doi-asserted-by":"publisher","DOI":"10.1002\/ajim.22103"},{"key":"2026061109500502000_55.6.1900953.72","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/09603123.2012.733938","article-title":"Cancer morbidity of residents living near an oil refinery plant in North-West Italy","volume":"23","author":"Salerno","year":"2013","journal-title":"Int J Environ Health Res"},{"key":"2026061109500502000_55.6.1900953.73","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2012-101198"},{"key":"2026061109500502000_55.6.1900953.74","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/jes.2012.63","article-title":"Impacts of land use on spatial distribution of mortality rates of cancers caused by naturally occurring asbestos","volume":"22","author":"Wei","year":"2012","journal-title":"J Expo Sci Environ Epidemiol"},{"key":"2026061109500502000_55.6.1900953.75","doi-asserted-by":"publisher","DOI":"10.1080\/19338240903390305"},{"key":"2026061109500502000_55.6.1900953.76","doi-asserted-by":"publisher","DOI":"10.1007\/s10653-013-9578-z"},{"key":"2026061109500502000_55.6.1900953.77","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/JOM.0b013e318250b5f5","article-title":"Mesothelioma associated with commercial use of vermiculite containing Libby amphibole","volume":"54","author":"Dunning","year":"2012","journal-title":"J Occup Environ Med"},{"key":"2026061109500502000_55.6.1900953.78","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e3181dc6d45"},{"key":"2026061109500502000_55.6.1900953.79","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1539-6924.2010.01411.x","article-title":"Potency factors for risk assessment at Libby, Montana","volume":"30","author":"Moolgavkar","year":"2010","journal-title":"Risk Anal"},{"key":"2026061109500502000_55.6.1900953.80","doi-asserted-by":"publisher","DOI":"10.4415\/ANN_14_02_02"},{"key":"2026061109500502000_55.6.1900953.81","first-page":"127","article-title":"Health impact of the exposure to fibres with fluoro-edenitic composition on the residents in Biancavilla (Sicily, Italy): mortality and hospitalization from current data","volume":"50","author":"Conti","year":"2014","journal-title":"Ann Ist Super Sanita"},{"key":"2026061109500502000_55.6.1900953.82","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12199-015-0501-3","article-title":"High-risk mesothelioma relation to meteorological and geological condition and distance from naturally occurring asbestos","volume":"21","author":"Abakay","year":"2016","journal-title":"Environ Health Prev Med"},{"key":"2026061109500502000_55.6.1900953.83","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2727"},{"key":"2026061109500502000_55.6.1900953.84","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgu227"},{"key":"2026061109500502000_55.6.1900953.85","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2013-102000"},{"key":"2026061109500502000_55.6.1900953.86","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2015-103105"},{"key":"2026061109500502000_55.6.1900953.87","doi-asserted-by":"publisher","DOI":"10.1002\/ajim.22063"},{"key":"2026061109500502000_55.6.1900953.88","doi-asserted-by":"publisher","DOI":"10.3109\/08958378.2012.683892"},{"key":"2026061109500502000_55.6.1900953.89","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/08958378.2017.1394931","article-title":"A 30-year mortality and respiratory morbidity study of refractory ceramic fiber workers","volume":"29","author":"LeMasters","year":"2017","journal-title":"Inhal Toxicol"},{"key":"2026061109500502000_55.6.1900953.90","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71109-X"},{"key":"2026061109500502000_55.6.1900953.91","first-page":"1","article-title":"Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42","volume":"7","year":"1987","journal-title":"IARC Monogr Eval Carcinog Risks Hum Suppl"},{"key":"2026061109500502000_55.6.1900953.92","unstructured":"International Agency for Cancer Research (IARC) . IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Silica and Some Silicates, Volume 42. Reviews of Human Carcinogens. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer, World Health Organization, 1987."},{"key":"2026061109500502000_55.6.1900953.93","unstructured":"International Agency for Cancer Research (IARC) . IARC Monographs \u2013 Arsenic, Metals, Fibres and Dusts, Volume 100 C. Reviews of Human Carcinogens. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer, World Health Organization, 2012."},{"key":"2026061109500502000_55.6.1900953.94","unstructured":"International Agency for Cancer Research (IARC) . IARC Monographs \u2013 Fluoro-edenite, silicon carbide fibres and whiskers, and single-walled and multi-walled carbon nanotub, Volume 111. Reviews of Human Carcinogens. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer, World Health Organization, 2014."},{"key":"2026061109500502000_55.6.1900953.95","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2013-101957"},{"key":"2026061109500502000_55.6.1900953.96","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10653-012-9504-9","article-title":"Geologic occurrences of erionite in the United States: an emerging national public health concern for respiratory disease","volume":"35","author":"Van Gosen","year":"2013","journal-title":"Environ Geochem Health"},{"key":"2026061109500502000_55.6.1900953.97","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1105887108"},{"key":"2026061109500502000_55.6.1900953.98","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201210-1911OC"},{"key":"2026061109500502000_55.6.1900953.99","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e3181b68cef"},{"key":"2026061109500502000_55.6.1900953.100","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0274(200103)39:3<262::AID-AJIM1014>3.0.CO;2-R"},{"key":"2026061109500502000_55.6.1900953.101","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/cas.12954","article-title":"Multiwalled carbon nanotubes intratracheally instilled into the rat lung induce development of pleural malignant mesothelioma and lung tumors","volume":"107","author":"Suzui","year":"2016","journal-title":"Cancer Sci"},{"key":"2026061109500502000_55.6.1900953.102","doi-asserted-by":"publisher","DOI":"10.1539\/joh.17-0102-RA"},{"key":"2026061109500502000_55.6.1900953.103","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00091-2016"},{"key":"2026061109500502000_55.6.1900953.104","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.canep.2014.02.014","article-title":"Familial malignant mesothelioma: a population-based study in central Italy (1980-2012)","volume":"38","author":"Ascoli","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"2026061109500502000_55.6.1900953.105","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27758"},{"key":"2026061109500502000_55.6.1900953.106","doi-asserted-by":"publisher","DOI":"10.1038\/ng.912"},{"key":"2026061109500502000_55.6.1900953.107","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2013.05.018"},{"key":"2026061109500502000_55.6.1900953.108","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.09.011"},{"key":"2026061109500502000_55.6.1900953.109","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","article-title":"BAP1, a tumor suppressor gene driving malignant mesothelioma","volume":"6","author":"Cheung","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"2026061109500502000_55.6.1900953.110","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3459"},{"key":"2026061109500502000_55.6.1900953.111","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.05.011"},{"key":"2026061109500502000_55.6.1900953.112","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/10937404.2016.1193361","article-title":"Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles","volume":"19","author":"Andujar","year":"2016","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"2026061109500502000_55.6.1900953.113","doi-asserted-by":"publisher","DOI":"10.1093\/mutage\/get008"},{"key":"2026061109500502000_55.6.1900953.114","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2011.01.001"},{"key":"2026061109500502000_55.6.1900953.115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2017.06.028","article-title":"Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma","volume":"405","author":"Betti","year":"2017","journal-title":"Cancer Lett"},{"key":"2026061109500502000_55.6.1900953.116","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13027-015-0022-0","article-title":"NLRP1 and NLRP3 polymorphisms in mesothelioma patients and asbestos exposed individuals a population-based autopsy study from North East Italy","volume":"10","author":"Borelli","year":"2015","journal-title":"Infect Agents Cancer"},{"key":"2026061109500502000_55.6.1900953.117","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1750-9378-7-25","article-title":"NLRP1 polymorphisms in patients with asbestos-associated mesothelioma","volume":"7","author":"Girardelli","year":"2012","journal-title":"Infect Agent Cancer"},{"key":"2026061109500502000_55.6.1900953.118","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.04.018"},{"key":"2026061109500502000_55.6.1900953.119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061253"},{"key":"2026061109500502000_55.6.1900953.120","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgv097"},{"key":"2026061109500502000_55.6.1900953.121","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl. 15","key":"2026061109500502000_55.6.1900953.122","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2018.36.15_suppl.8504","article-title":"Inherited predisposition to malignant mesothelioma (MM) due to mutations in DNA repair genes","volume":"36","author":"Hassan","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026061109500502000_55.6.1900953.123","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840901)54:5<951::AID-CNCR2820540536>3.0.CO;2-A"},{"key":"2026061109500502000_55.6.1900953.124","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/cam4.656","article-title":"Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database","volume":"5","author":"Farioli","year":"2016","journal-title":"Cancer Med"},{"key":"2026061109500502000_55.6.1900953.125","unstructured":"International Agency for Cancer Research (IARC) . IARC Monographs \u2013 Malaria and Some Polyomaviruses (SV40, BK, JC, and Merkel Cell Viruses), Volume 104. Reviews of Human Carcinogens. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer, World Health Organization, 2014."},{"key":"2026061109500502000_55.6.1900953.126","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0274(199711)32:5<445::AID-AJIM3>3.0.CO;2-R"},{"key":"2026061109500502000_55.6.1900953.127","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1345"},{"key":"2026061109500502000_55.6.1900953.128","doi-asserted-by":"publisher","DOI":"10.3109\/08958378.2015.1051640"},{"key":"2026061109500502000_55.6.1900953.129","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs513"},{"key":"2026061109500502000_55.6.1900953.130","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14794-0"},{"key":"2026061109500502000_55.6.1900953.131","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200907-1020OC"},{"key":"2026061109500502000_55.6.1900953.132","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00408-013-9526-9","article-title":"Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos","volume":"192","author":"Bayram","year":"2014","journal-title":"Lung"},{"key":"2026061109500502000_55.6.1900953.133","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205205"},{"key":"2026061109500502000_55.6.1900953.134","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.05.017"},{"key":"2026061109500502000_55.6.1900953.135","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6671"},{"key":"2026061109500502000_55.6.1900953.136","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051185"},{"key":"2026061109500502000_55.6.1900953.137","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cca.2014.02.024","article-title":"Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"433","author":"Hu","year":"2014","journal-title":"Clin Chim Acta"},{"key":"2026061109500502000_55.6.1900953.138","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1115050"},{"key":"2026061109500502000_55.6.1900953.139","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.18632\/oncotarget.14712","article-title":"Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: evidence from a meta-analysis","volume":"8","author":"Pei","year":"2017","journal-title":"Oncotarget"},{"key":"2026061109500502000_55.6.1900953.140","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182572e83"},{"key":"2026061109500502000_55.6.1900953.141","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.lungcan.2015.09.021","article-title":"Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma","volume":"90","author":"Santarelli","year":"2015","journal-title":"Lung Cancer"},{"key":"2026061109500502000_55.6.1900953.142","doi-asserted-by":"crossref","first-page":"82700","DOI":"10.18632\/oncotarget.12408","article-title":"Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers","volume":"7","author":"Bononi","year":"2016","journal-title":"Oncotarget"},{"key":"2026061109500502000_55.6.1900953.143","doi-asserted-by":"crossref","first-page":"9280170","DOI":"10.1155\/2017\/9280170","article-title":"Circulating miR-132-3p as a candidate diagnostic biomarker for malignant mesothelioma","volume":"2017","author":"Weber","year":"2017","journal-title":"Dis Markers"},{"key":"2026061109500502000_55.6.1900953.144","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1130"},{"key":"2026061109500502000_55.6.1900953.145","doi-asserted-by":"crossref","first-page":"5756102","DOI":"10.1155\/2017\/5756102","article-title":"Serum HMGB1 as a potential biomarker for patients with asbestos-related diseases","volume":"2017","author":"Ying","year":"2017","journal-title":"Dis Markers"},{"key":"2026061109500502000_55.6.1900953.146","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0472"},{"key":"2026061109500502000_55.6.1900953.147","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046091"},{"key":"2026061109500502000_55.6.1900953.148","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezs521"},{"key":"2026061109500502000_55.6.1900953.149","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/cas.12687","article-title":"Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: a patient-based study","volume":"106","author":"Xu","year":"2015","journal-title":"Cancer Sci"},{"key":"2026061109500502000_55.6.1900953.150","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00408-016-9868-1","article-title":"Evaluation of new biomarkers in the prediction of malignant mesothelioma in subjects with environmental asbestos exposure","volume":"194","author":"Demir","year":"2016","journal-title":"Lung"},{"key":"2026061109500502000_55.6.1900953.151","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12014-016-9103-3","article-title":"ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms","volume":"13","author":"Morr\u00e9","year":"2016","journal-title":"Clin Proteomics"},{"key":"2026061109500502000_55.6.1900953.152","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12885-017-3375-5","article-title":"Calretinin as a blood-based biomarker for mesothelioma","volume":"17","author":"Johnen","year":"2017","journal-title":"BMC Cancer"},{"key":"2026061109500502000_55.6.1900953.153","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2217\/bmm.11.18","article-title":"Soluble markers for diagnosis of malignant pleural mesothelioma","volume":"5","author":"Cristaudo","year":"2011","journal-title":"Biomark Med"},{"key":"2026061109500502000_55.6.1900953.154","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00226111"},{"key":"2026061109500502000_55.6.1900953.155","doi-asserted-by":"crossref","first-page":"259","DOI":"10.21037\/tlcr.2017.05.06","article-title":"Diagnostic and prognostic biomarkers for malignant mesothelioma: an update","volume":"6","author":"Chen","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"2026061109500502000_55.6.1900953.156","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.12.004"},{"key":"2026061109500502000_55.6.1900953.157","doi-asserted-by":"crossref","first-page":"244","DOI":"10.21037\/atm.2017.06.60","article-title":"Diagnosis and prognosis-review of biomarkers for mesothelioma","volume":"5","author":"Sun","year":"2017","journal-title":"Ann Transl Med"},{"key":"2026061109500502000_55.6.1900953.158","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200802-258OC"},{"key":"2026061109500502000_55.6.1900953.159","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31820db377"},{"key":"2026061109500502000_55.6.1900953.160","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-010-0580-2"},{"key":"2026061109500502000_55.6.1900953.161","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00420-013-0853-1","article-title":"Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers","volume":"87","author":"Felten","year":"2014","journal-title":"Int Arch Occup Environ Health"},{"key":"2026061109500502000_55.6.1900953.162","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000355687","article-title":"Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos","volume":"86","author":"Filiberti","year":"2014","journal-title":"Oncology"},{"key":"2026061109500502000_55.6.1900953.163","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3892\/mco.2013.197","article-title":"Retrospective analysis of large-scale research screening of construction workers for the early diagnosis of mesothelioma","volume":"2","author":"Hirohashi","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"2026061109500502000_55.6.1900953.164","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-10-0346"},{"key":"2026061109500502000_55.6.1900953.165","doi-asserted-by":"publisher","DOI":"10.1136\/oem.2009.048629"},{"key":"2026061109500502000_55.6.1900953.166","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1179\/2049396714Y.0000000087","article-title":"Asbestos-related occupational cancers compensated under the Spanish National Insurance System, 1978-2011","volume":"21","author":"Garc\u00eda-G\u00f3mez","year":"2015","journal-title":"Int J Occup Environ Health"},{"key":"2026061109500502000_55.6.1900953.167","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ajim.22106","article-title":"Compensation of pleural mesothelioma in France: data from the French National Mesothelioma Surveillance Programme","volume":"56","author":"Chamming's","year":"2013","journal-title":"Am J Ind Med"},{"key":"2026061109500502000_55.6.1900953.168","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1984.00350140139020"},{"key":"2026061109500502000_55.6.1900953.169","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/64.2.200"},{"key":"2026061109500502000_55.6.1900953.170","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(58)91439-9","article-title":"Pleural biopsy in the diagnosis of pleural effusion; a report of 200 cases","volume":"2","author":"Mestitz","year":"1958","journal-title":"Lancet"},{"key":"2026061109500502000_55.6.1900953.171","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1012685"},{"key":"2026061109500502000_55.6.1900953.172","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1990.00390180034005"},{"key":"2026061109500502000_55.6.1900953.173","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.211.3.r99jn03657"},{"key":"2026061109500502000_55.6.1900953.174","doi-asserted-by":"publisher","DOI":"10.1159\/000080638"},{"key":"2026061109500502000_55.6.1900953.175","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13079-6"},{"key":"2026061109500502000_55.6.1900953.176","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-0299"},{"key":"2026061109500502000_55.6.1900953.177","doi-asserted-by":"publisher","DOI":"10.1510\/icvts.2010.255893"},{"key":"2026061109500502000_55.6.1900953.178","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23034"},{"key":"2026061109500502000_55.6.1900953.179","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/JTO.0b013e31823e0667","article-title":"Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma","volume":"7","author":"Pinelli","year":"2012","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.180","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.137018"},{"key":"2026061109500502000_55.6.1900953.181","doi-asserted-by":"publisher","DOI":"10.1097\/LBR.0000000000000145"},{"key":"2026061109500502000_55.6.1900953.182","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5090\/kjtcs.2014.47.2.124","article-title":"Is there a role for a needle thoracoscopic pleural biopsy under local anesthesia for pleural effusions?","volume":"47","author":"Son","year":"2014","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"2026061109500502000_55.6.1900953.183","first-page":"MC01","article-title":"Medical thoracoscopy vs closed pleural biopsy in pleural effusions: a randomized controlled study","volume":"8","author":"Haridas","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"2026061109500502000_55.6.1900953.184","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ejcdt.2013.08.012","article-title":"Diagnosis of exudative pleural effusion using ultrasound guided versus medical thoracoscopic pleural biopsy","volume":"62","author":"Mohamed","year":"2013","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"2026061109500502000_55.6.1900953.185","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jtho.2018.08.001","article-title":"Surgery in malignant pleural mesothelioma","volume":"13","author":"Bueno","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.186","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezs648"},{"key":"2026061109500502000_55.6.1900953.187","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24886"},{"key":"2026061109500502000_55.6.1900953.188","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.thorsurg.2012.10.002","article-title":"Surgical management of malignant pleural mesothelioma","volume":"23","author":"Yanagawa","year":"2013","journal-title":"Thorac Surg Clin"},{"key":"2026061109500502000_55.6.1900953.189","first-page":"534","article-title":"Video-atlas of radical pleurectomy for malignant pleural mesothelioma","volume":"1","author":"B\u00f6l\u00fckbas","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"2026061109500502000_55.6.1900953.190","unstructured":"B\u00f6l\u00fckbas S , Eberlein M , Schirren J . Pleurectomy\/decortication for the treatment of malignant pleural mesothelioma. In: Kuzdzal J , ed. ESTS Textbook of Thoracic Surgery. Cracow, Medicina Praktyczna, 2014; pp. 313\u2013320."},{"key":"2026061109500502000_55.6.1900953.191","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.11.005"},{"key":"2026061109500502000_55.6.1900953.192","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9969(77)90111-X"},{"key":"2026061109500502000_55.6.1900953.193","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0124-RA"},{"key":"2026061109500502000_55.6.1900953.194","unstructured":"Churg A , Roggli V , Galateau-Salle F . Tumours of the pleura. In: Travis WD , Brambilla E , Burke AP , et al. , eds. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, International Agency for Research on Cancer, 2015."},{"key":"2026061109500502000_55.6.1900953.195","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01254-2018"},{"key":"2026061109500502000_55.6.1900953.196","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.6.1798"},{"key":"2026061109500502000_55.6.1900953.197","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2018.07.041","article-title":"Highlights of the 14th International Mesothelioma Interest Group meeting: pathologic separation of benign from malignant mesothelial proliferations and histologic\/molecular analysis of malignant mesothelioma subtypes","volume":"124","author":"Churg","year":"2018","journal-title":"Lung Cancer"},{"key":"2026061109500502000_55.6.1900953.198","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/PAS.0000000000000529","article-title":"Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"2026061109500502000_55.6.1900953.199","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.200","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.humpath.2017.07.015","article-title":"The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell\/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center","volume":"67","author":"Marchevsky","year":"2017","journal-title":"Hum Pathol"},{"key":"2026061109500502000_55.6.1900953.201","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5858\/arpa.2015-0508-LE","article-title":"Immunohistochemistry for NF2, LATS1\/2, and YAP\/TAZ fails to separate benign from malignant mesothelial proliferations","volume":"140","author":"Sheffield","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"2026061109500502000_55.6.1900953.202","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31826915f1"},{"key":"2026061109500502000_55.6.1900953.203","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jtho.2016.09.123","article-title":"The IASLC Mesothelioma Staging Project: improving staging of a rare disease through international participation","volume":"11","author":"Pass","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.204","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","article-title":"The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Nowak","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.205","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma","volume":"11","author":"Rusch","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.206","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.jtho.2016.09.121","article-title":"The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Rice","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.207","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2003.12.001"},{"key":"2026061109500502000_55.6.1900953.208","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/SLA.0000000000000903","article-title":"Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients","volume":"260","author":"Sugarbaker","year":"2014","journal-title":"Ann Surg"},{"key":"2026061109500502000_55.6.1900953.209","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezv422"},{"key":"2026061109500502000_55.6.1900953.210","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2005.11.044"},{"key":"2026061109500502000_55.6.1900953.211","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2016.06.069"},{"key":"2026061109500502000_55.6.1900953.212","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jtcvs.2004.10.034","article-title":"Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications","volume":"129","author":"Erasmus","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026061109500502000_55.6.1900953.213","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","article-title":"Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma","volume":"11","author":"Bill\u00e9","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.214","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.lungcan.2016.01.017","article-title":"Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET\/CT in local thoracic staging of malignant pleural mesothelioma","volume":"94","author":"Martini","year":"2016","journal-title":"Lung Cancer"},{"key":"2026061109500502000_55.6.1900953.215","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.09.3519"},{"key":"2026061109500502000_55.6.1900953.216","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2008.03.034"},{"key":"2026061109500502000_55.6.1900953.217","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2009.05.022"},{"key":"2026061109500502000_55.6.1900953.218","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezr251"},{"key":"2026061109500502000_55.6.1900953.219","doi-asserted-by":"publisher","DOI":"10.1510\/icvts.2009.213611"},{"key":"2026061109500502000_55.6.1900953.220","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1445-2197.2009.05060.x","article-title":"Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy","volume":"79","author":"Alvarez","year":"2009","journal-title":"ANZ J Surg"},{"key":"2026061109500502000_55.6.1900953.221","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000181"},{"key":"2026061109500502000_55.6.1900953.222","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J Clin Oncol"},{"key":"2026061109500502000_55.6.1900953.223","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.3.723"},{"key":"2026061109500502000_55.6.1900953.224","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/JTO.0000000000000661","article-title":"A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma: a review of 12 years\u2019 experience","volume":"10","author":"Opitz","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.225","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.226","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S1470-2045(18)30294-8","article-title":"Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis","volume":"19","author":"Psallidas","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026061109500502000_55.6.1900953.227","doi-asserted-by":"crossref","first-page":"507","DOI":"10.21037\/tlcr.2018.07.08","article-title":"The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey","volume":"7","author":"Ben Bouazza","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"2026061109500502000_55.6.1900953.228","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60418-9"},{"key":"2026061109500502000_55.6.1900953.229","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182208e3f"},{"key":"2026061109500502000_55.6.1900953.230","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.athoracsur.2017.09.036","article-title":"National trends in the epidemiology of malignant pleural mesothelioma: a national cancer data base study","volume":"105","author":"Saddoughi","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"2026061109500502000_55.6.1900953.231","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/ejcts\/ezx427","article-title":"Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma","volume":"53","author":"Nelson","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026061109500502000_55.6.1900953.232","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2017.73.8401","article-title":"Long-term survival outcomes of cancer-directed surgery for malignant pleural mesothelioma: propensity score matching analysis","volume":"35","author":"Nelson","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026061109500502000_55.6.1900953.233","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2026061109500502000_55.6.1900953.234","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.05.014"},{"key":"2026061109500502000_55.6.1900953.235","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.lungcan.2018.10.009","article-title":"Real-life treatment practice for malignant pleural mesothelioma in Belgium","volume":"125","author":"Rosskamp","year":"2018","journal-title":"Lung Cancer"},{"key":"2026061109500502000_55.6.1900953.236","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70149-8"},{"key":"2026061109500502000_55.6.1900953.237","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000064"},{"key":"2026061109500502000_55.6.1900953.238","first-page":"164","article-title":"Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey","volume":"19","author":"Kucukoner","year":"2014","journal-title":"J BUON"},{"issue":"Suppl. 1","key":"2026061109500502000_55.6.1900953.239","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0169-5002(16)30212-4","article-title":"A feasibility study comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma: the MARS 2 study","volume":"91","author":"Lim","year":"2016","journal-title":"Lung Cancer"},{"key":"2026061109500502000_55.6.1900953.240","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000499"},{"key":"2026061109500502000_55.6.1900953.241","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.01.003"},{"key":"2026061109500502000_55.6.1900953.242","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2016.08.001"},{"key":"2026061109500502000_55.6.1900953.243","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2016.6770","article-title":"Effect of radiotherapy on painful bone metastases: a secondary analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23","volume":"3","author":"McDonald","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026061109500502000_55.6.1900953.244","doi-asserted-by":"publisher","DOI":"10.1378\/chest.108.3.754"},{"key":"2026061109500502000_55.6.1900953.245","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2007.05.022"},{"key":"2026061109500502000_55.6.1900953.246","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00079407"},{"key":"2026061109500502000_55.6.1900953.247","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601957"},{"key":"2026061109500502000_55.6.1900953.248","doi-asserted-by":"crossref","unstructured":"Chapman E , Berenstein EG , Di\u00e9guez M , et al. Radiotherapy for malignant pleural mesothelioma. Cochrane Database Syst Rev 2006: CD003880.","DOI":"10.1002\/14651858.CD003880.pub4"},{"key":"2026061109500502000_55.6.1900953.249","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30095-X"},{"key":"2026061109500502000_55.6.1900953.250","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01678"},{"key":"2026061109500502000_55.6.1900953.251","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00208-9"},{"key":"2026061109500502000_55.6.1900953.252","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000078"},{"key":"2026061109500502000_55.6.1900953.253","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ijrobp.2015.06.029","article-title":"Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure, and prognostic factors","volume":"93","author":"Minatel","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026061109500502000_55.6.1900953.254","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.2675"},{"key":"2026061109500502000_55.6.1900953.255","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.lungcan.2015.06.018","article-title":"Second line therapy in malignant pleural mesothelioma: a systematic review","volume":"89","author":"Buikhuisen","year":"2015","journal-title":"Lung Cancer"},{"key":"2026061109500502000_55.6.1900953.256","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182333df5"},{"key":"2026061109500502000_55.6.1900953.257","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70125-6"},{"key":"2026061109500502000_55.6.1900953.258","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtho.2016.01.014","article-title":"A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes","volume":"11","author":"Buikhuisen","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.259","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ec18db"},{"key":"2026061109500502000_55.6.1900953.260","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318260dfb9"},{"key":"2026061109500502000_55.6.1900953.261","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0804"},{"key":"2026061109500502000_55.6.1900953.262","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.11.014"},{"key":"2026061109500502000_55.6.1900953.263","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.06.008"},{"key":"2026061109500502000_55.6.1900953.264","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.05.008"},{"key":"2026061109500502000_55.6.1900953.265","first-page":"3441","article-title":"Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study","volume":"29","author":"Ralli","year":"2009","journal-title":"Anticancer Res"},{"key":"2026061109500502000_55.6.1900953.266","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/bjc.2012.44","article-title":"First-line (chemo)therapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial","volume":"106","author":"Arrieta","year":"2012","journal-title":"Br J Cancer"},{"key":"2026061109500502000_55.6.1900953.267","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s12094-013-1015-3","article-title":"Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular (chemo)therapy regimens","volume":"15","author":"Habib","year":"2013","journal-title":"Clin Transl Oncol"},{"key":"2026061109500502000_55.6.1900953.268","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3816\/CLC.2010.n.005","article-title":"Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"11","author":"Katirtzoglou","year":"2010","journal-title":"Clin Lung Cancer"},{"key":"2026061109500502000_55.6.1900953.269","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CAD.0b013e32834d7a1c","article-title":"A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma","volume":"23","author":"Kovac","year":"2012","journal-title":"Anticancer Drugs"},{"key":"2026061109500502000_55.6.1900953.270","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3892\/mco.2013.118","article-title":"Methotrexate and gemcitabine combination (chemo)therapy for the treatment of malignant pleural mesothelioma","volume":"1","author":"Kuribayashi","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"2026061109500502000_55.6.1900953.271","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"2026061109500502000_55.6.1900953.272","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.368"},{"key":"2026061109500502000_55.6.1900953.273","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.05.111"},{"key":"2026061109500502000_55.6.1900953.274","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.5869"},{"key":"2026061109500502000_55.6.1900953.275","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.05.006"},{"key":"2026061109500502000_55.6.1900953.276","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","article-title":"SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)","volume":"10","author":"Ou","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.277","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31828c2b26"},{"key":"2026061109500502000_55.6.1900953.278","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.024"},{"key":"2026061109500502000_55.6.1900953.279","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.06.011"},{"key":"2026061109500502000_55.6.1900953.280","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318248242c"},{"key":"2026061109500502000_55.6.1900953.281","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318229586e"},{"key":"2026061109500502000_55.6.1900953.282","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318191520c"},{"key":"2026061109500502000_55.6.1900953.283","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00037310"},{"key":"2026061109500502000_55.6.1900953.284","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70056-2"},{"key":"2026061109500502000_55.6.1900953.285","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.04.001"},{"key":"2026061109500502000_55.6.1900953.286","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/COC.0b013e3181cae90e","article-title":"Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study","volume":"34","author":"Tourkantonis","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"2026061109500502000_55.6.1900953.287","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70381-4"},{"key":"2026061109500502000_55.6.1900953.288","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for (chemo)therapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026061109500502000_55.6.1900953.289","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026061109500502000_55.6.1900953.290","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.3649"},{"key":"2026061109500502000_55.6.1900953.291","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed\/cisplatin for (chemo)therapy-na\u00efve patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026061109500502000_55.6.1900953.292","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026061109500502000_55.6.1900953.293","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance defactinib versus placebo after first-line (chemo)therapy in patients with merlin-stratified pleural mesothelioma: COMMAND \u2013 a double-blind, randomized, phase II study","volume":"37","author":"Fennell","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026061109500502000_55.6.1900953.294","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026061109500502000_55.6.1900953.295","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9"},{"key":"2026061109500502000_55.6.1900953.296","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0613-x"},{"key":"2026061109500502000_55.6.1900953.297","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30765-4"},{"key":"2026061109500502000_55.6.1900953.298","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma: a phase II study","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026061109500502000_55.6.1900953.299","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026061109500502000_55.6.1900953.300","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2018.36.15_suppl.8503","article-title":"DREAM: a phase II study of durvalumab with first line (chemo)therapy in mesothelioma \u2013 first results","volume":"36","author":"Nowak","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026061109500502000_55.6.1900953.301","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.lungcan.2018.07.007","article-title":"Current efforts in research of pleural mesothelioma \u2013 an analysis of the ClinicalTrials.gov registry","volume":"124","author":"S\u00fcveg","year":"2018","journal-title":"Lung Cancer"},{"key":"2026061109500502000_55.6.1900953.302","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.034"},{"key":"2026061109500502000_55.6.1900953.303","first-page":"CD012605","article-title":"Radical multimodality therapy for malignant pleural mesothelioma","volume":"1","author":"Abdel-Rahman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026061109500502000_55.6.1900953.304","doi-asserted-by":"crossref","first-page":"562","DOI":"10.21037\/tlcr.2018.10.02","article-title":"Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations","volume":"7","author":"De Bondt","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"2026061109500502000_55.6.1900953.305","unstructured":"Travis WD , Brambilla E , Burke AP , et al. WHO Classification Tumours of the Lung and Pleura. 4th Edn. Lyon, IARC Press, 2015."},{"key":"2026061109500502000_55.6.1900953.306","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA1-Associated Protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study","volume":"11","author":"Righi","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.307","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00349-2018"},{"key":"2026061109500502000_55.6.1900953.308","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj073"},{"key":"2026061109500502000_55.6.1900953.309","doi-asserted-by":"publisher","DOI":"10.1136\/thx.54.3.238"},{"key":"2026061109500502000_55.6.1900953.310","first-page":"631","article-title":"\u201cIt sort of hit me like a baseball bat between the eyes\u201d: a qualitative study of the psychosocial experiences of mesothelioma patients and carers","volume":"27","author":"Girgis","year":"2019","journal-title":"Support Care Cancer"},{"key":"2026061109500502000_55.6.1900953.311","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050152"},{"key":"2026061109500502000_55.6.1900953.312","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60727-8"},{"key":"2026061109500502000_55.6.1900953.313","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0063-2016"},{"key":"2026061109500502000_55.6.1900953.314","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"2026061109500502000_55.6.1900953.315","first-page":"41","article-title":"Combination immunotherapy superior to monotherapy in patients with melanoma","volume":"8","author":"Doyle","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"2026061109500502000_55.6.1900953.316","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1200\/JCO.2016.71.2109","article-title":"Differences in treatment effect size between overall survival and progression-free survival in immunotherapy trials: a meta-epidemiologic study of trials with results posted at clinicaltrials.gov","volume":"35","author":"Tan","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026061109500502000_55.6.1900953.317","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2026061109500502000_55.6.1900953.318","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.08.069"},{"key":"2026061109500502000_55.6.1900953.319","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2026061109500502000_55.6.1900953.320","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348"},{"key":"2026061109500502000_55.6.1900953.321","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824"},{"key":"2026061109500502000_55.6.1900953.322","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.09.001"},{"key":"2026061109500502000_55.6.1900953.323","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140559"},{"key":"2026061109500502000_55.6.1900953.324","doi-asserted-by":"publisher","DOI":"10.1038\/nm1196"},{"key":"2026061109500502000_55.6.1900953.325","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501"},{"key":"2026061109500502000_55.6.1900953.326","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1101"},{"key":"2026061109500502000_55.6.1900953.327","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.2016.71.3230","article-title":"Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1-deficient thoracic cancers","volume":"35","author":"Beddowes","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026061109500502000_55.6.1900953.328","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3947"},{"key":"2026061109500502000_55.6.1900953.329","doi-asserted-by":"publisher","DOI":"10.1038\/nature22798"},{"key":"2026061109500502000_55.6.1900953.330","doi-asserted-by":"crossref","first-page":"E429","DOI":"10.3390\/ijms20020429","article-title":"BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment","volume":"20","author":"Guazzelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026061109500502000_55.6.1900953.331","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30621-6"},{"key":"2026061109500502000_55.6.1900953.332","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.95"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00953-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:50:33Z","timestamp":1781196633000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00953-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":332,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,11]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1183\/13993003.00953-2019"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00953-2019","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,25]]}}}